Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
This article was originally published in The Pink Sheet Daily
Executive Summary
Biocon will manufacture biogeneric of Amgen’s Neupogen for Abraxis, the firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Biocon Announces Partnership With U.S. Start-Up To Develop Novel Oncologic Drugs
India’s largest biotech teams with Baltimore’s IATRICa to develop immunoconjugates to fight cancers and infectious diseases.
Biocon Announces Partnership With U.S. Start-Up To Develop Novel Oncologic Drugs
India’s largest biotech teams with Baltimore’s IATRICa to develop immunoconjugates to fight cancers and infectious diseases.
Alpharma To Market Institut Biochimique’s Flector NSAID Patch In U.S.
Alpharma plans to double its in-house sales force from 200 to 400 reps, plus add 200 contract sales reps to market Flector.